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Although older patients undergoing allogeneic hematopoietic stem cell transplantation (HCT) may experience
higher morbidity, the impact of chronic graft-versus-host disease (GVHD) on quality of life (QOL) and survival
outcomes for older compared with younger patients is currently unknown. We utilized data of patients with
moderate or severe chronic GVHD (N ¼ 522, 1661 follow-up visits, a total of 2183 visits) from the Chronic
GVHD Consortium, a prospective observational multicenter cohort. We examined the relationship between
age group (adolescent and young adult, “AYA,” 18 to 40 years; “middle-aged,” 41 to 59 years; and
“older,”  60 years) and QOL (Functional Assessment of Cancer Therapy-Bone Marrow Transplantation [FACT-
BMT]), physical functioning (Human Activity Proﬁle [HAP]), functional status (2-minute walk test [2MWT]),
nonrelapse mortality, and overall survival. Because of multiple testing, P values < .01 were considered sig-
niﬁcant. This study included 115 (22%) AYA, 279 (53%) middle-aged, and 128 (25%) older patients with
moderate (58%) or severe (42%) chronic GVHD. Despite more physical limitations in older patients as
measured by worse functional status (shorter 2MWT [P < .001] and lower HAP scores [P < .001]) relative to
AYA and middle-aged patients, older patients reported better QOL (FACT-BMT, P ¼ .004) compared with
middle-aged patients and similar to AYA patients (P ¼ .99). Nonrelapse mortality and overall survival were
similar between the age groups. Therefore, despite higher physical and functional limitations, older patients
who are selected to undergo HSCT and survive long enough to develop moderate or severe chronic GVHD
have preserved QOL and similar overall survival and nonrelapse mortality when compared with younger
patients. Therefore, we did not ﬁnd evidence that older age is associated with worse outcomes in patients
with moderate or severe chronic GVHD.
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14.05.001Older patients undergoing allogeneic hematopoietic stem
cell transplantation (HCT) may experience a high degree of
morbidity from transplantation-related complications [1-4],
and this concern has historically limited the use of HCT for
some older patients. In many studies, age has been shown to
be a negative prognostic factor for survival and associated
with higher transplantation-related mortality in patients
undergoing HCT [5-8]. However, in others, age was notTransplantation.
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for other comorbidities are incorporated in the analyses [9-
12]. The relationship between age and the long-term expe-
rience of HCT survivors is not known. Speciﬁcally, studies
examining the impact of older age on quality of life (QOL) and
physical functioning of HCT survivors are limited and have
yielded conﬂicting results [1-5].
Chronic graft-versus-host disease (GVHD) is the leading
cause of nonrelapse mortality in patients surviving more
than 2 years after HCT [13-17]. It is also a signiﬁcant source of
morbidity, physical and psychological symptom burden,
impaired QOL, and lower functional status in HCT survivors
[13,14,18-20]. Moreover, the severity of chronic GVHD has
been shown to correlate with patients’ QOL after HCT [21].
Given the toll of chronic GVHD on patients’ QOL, it is
particularly important to identify speciﬁc populations at high
risk for signiﬁcant complications if chronic GVHD occurs.
This would allow for more intensive targeted interventions
to improve the clinical outcomes of HCT survivors at risk. Age
is an important factor to consider, as older patients with
chronic GVHD may, in theory, experience more limitations
compared with younger patients. To date, however, there
have been no studies assessing the burden of chronic GVHD
on patients in different age groups. Given the paucity of data
and the increasing number of older patients undergoing HCT,
a better understanding of the relationship between age and
the QOL, physical functioning, and survival in patients with
chronic GVHD is clearly warranted.
We retrospectively analyzed prospectively collected
observational cohort data from the Chronic GVHD Con-
sortium to examine whether the age of a patient with
moderate or severe chronic GVHD is associated with major
clinical outcomes such as QOL, symptom burden, functional
ability, and mortality.
METHODS
Chronic GVHD Observational Cohort
The Chronic GVHD Consortium is a multicenter observational cohort
study of patients affected by chronic GVHD [22]. The protocol was approved
by the institutional review board at each of the 9 participating sites (Table 1),
and all subjects provided written informed consent. The cohort includes
recipients of allogeneic HCT, age 2 or older, with chronic GVHD requiring
systemic immunosuppression. For the purpose of this analysis, we only
focused on patients age 18 or older. Cases are classiﬁed as either incident
(enrollment less than 3 months after the diagnosis of chronic GVHD) or
prevalent (enrollment at 3 months or more after the diagnosis of chronic
GVHD but less than 3 years after transplantation). Patients with primary
disease relapse or inability to comply with study procedures were excluded.
Patients and clinicians reported standardized information about chronic
GVHD symptoms and organ involvement at the time of study enrollment
and at serial follow-up visits every 6months. Incident cases had 1 additional
evaluation at 3 months after enrollment. Chronic GVHD global severity ac-
cording to the National Institutes of Health (NIH) chronic GVHD consensus is
scored according to the objective criteria for each organ involved, which is
summarized for an overall score of mild, moderate, or severe [23]. Only
patients with moderate or severe chronic GVHD at enrollment were
included for this analysis, as there were too few patients with mild chronic
GVHD to analyze. Therefore, we focused on patients with the highest burden
of disease, as the severity of chronic GVHD as measured by NIH criteria is
associated with signiﬁcant compromise in multiple domains of QOL [21].
Additional measures examine the impact of chronic GVHD on functional
ability, symptom burden, and QOL. The assessments performed reﬂect the
recommendation of the NIH Consensus Conference.
Patient-reported Outcomes
To assess QOL, we used the Functional Assessment of Cancer Therapy
(FACT)-Bone Marrow Transplantation (BMT) [24]. The FACT-BMT is a 47-
item self-report questionnaire that measures the effect of cancer therapy
on multiple QOL domains, including physical, functional, social/family,
emotional well-being, and BMT-speciﬁc concerns, with higher scoresindicating greater QOL. Individual domain scores can be summarized to give
a total FACT-BMT score (including all subscales) or a FACT-Trial Outcome
Index (TOI) (physical þ functional þ BMT subscale). Ten items of the BMT
subscale do not contribute to the scoring of the instrument and were,
therefore, not administered in this study.
To assess overall health and functioning, we utilized the Medical
Outcomes Study 36-item Short-Form Health Survey (SF-36), a 36-item self-
report questionnaire [25-27]. The instrument examines the following do-
mains: physical functioning, role functioning-physical, bodily pain, general
health, vitality, social functioning, role functioning-emotional, and mental
health. Two summary scales from the SF-36 include the physical component
score and the mental component score, which are normalized to the general
population with a mean of 50 and a standard deviation of 10.
To assess the symptom burden of chronic GVHD, we utilized the Lee
Chronic GVHD Symptom Scale, which is a 30-item, 7-subscale symptom
scale that evaluates adverse effects of chronic GVHD on skin, vitality, lung,
nutritional status, psychological functioning, eye, and mouth symptoms.
Scores range from 0 to 100 and higher scores indicate greater symptom
burden [28]. To assess physical functioning, we used the Human Activity
Proﬁle (HAP), a 94-item self-reported assessment of physical ﬁtness and
energy expenditure [29,30]. Respondents indicate whether they never did,
have stopped, or are still performing listed activities. A maximum activity
score, an adjusted activity score, and a modiﬁed adjusted activity score
speciﬁc for the HCT population were calculated.
Functional Assessments
We used the 2-minute walk test (2-MWT) to assess functional status.
The test entails instructing patients towalk a 25-foot coursewith 180 degree
turns at each end, and the total distance covered in 2 minutes is recorded
[22].
Statistical Methods
Patients were divided into 3 age groups based on their age at the time of
study enrollment: adolescent and young adult or “AYA” (18 to 40 years),
“middle aged” (41 to 59 years), and “older”(60 years). We used descriptive
statistics, including median and range or frequencies and percentages, ac-
cording to the nature of data to summarize patient, transplantation, and
chronic GVHD characteristics of study subjects. In these analyses, we utilized
all available cohort data (through January 31, 2013) from enrollment and
serial follow-up visits.
To account for within-patient correlation, we used linear mixed models
with random patient effects for continuous outcomes. To study the rela-
tionship of age with QOL, 2-MWT, and HAP measures, we constructed
multivariable linear mixed models using all visit data. We adjusted for sig-
niﬁcant covariates including study site, race, Hispanic ethnicity, patient
gender, month from HCT to cohort enrollment, disease diagnosis, condi-
tioning regimen intensity, transplantation source, NIH global chronic GVHD
severity, donor-patient gender match, donor match, Sorror comorbidity
index, and overlap versus classic chronic GVHD subtype. Karnofsky perfor-
mance status was not included as a covariate because it was felt to be a
collinear variable strongly associated with functional status, 1 of the main
outcomes of interest.
We used multivariable Cox regression models to study the association
between age group with overall survival and nonrelapse mortality. We
calculated overall survival from the time of enrollment, with patients
censored at date last known alive. We deﬁned nonrelapse mortality as death
without prior relapse. The models adjusted for signiﬁcant covariates
including study site, month from HCT to cohort enrollment, platelet count
(<100,000, higher), Karnofsky performance status, conditioning regimen
intensity, serum bilirubin level (2, higher), NIH global chronic GVHD
severity, and overlap versus classic chronic GVHD type. Both the adjusted
and unadjusted overall survival and nonrelapse mortality are reported.
Considering multiple testing, type I error was controlled by treating a
2-sided P < .01 as statistically signiﬁcant.
RESULTS
Study Participants
Five hundred twenty-two adult patients withmoderate or
severe chronic GVHD (1661 follow-up visits, a total of 2183
visits) were enrolled during the study period. Therewere 115
(22%) AYA, 279 (53%) middle-aged, and 128 (25%) older
patients with moderate (58%) or severe (42%) chronic GVHD
at enrollment. Table 1 depicts patient, disease, and trans-
plantation characteristics. At study enrollment, older patients
were similar to AYA and middle-aged patients for gender,
Table 1
Participants Characteristics at the Time of Study Enrollment
Characteristic Categories Age  40
(n ¼ 115)
Age 41-59
(n ¼ 279)
Age  60
(n ¼ 128)
P Value
Study site, n (%) Fred Hutchinson Cancer Research Center 49 (43%) 115 (41%) 72 (56%) P ¼ .09
University of Minnesota 11 (10%) 29 (10%) 12 (9%)
Dana-Farber Cancer Institute 13 (11%) 39 (14%) 11 (9%)
Stanford University Medical Center 22 (19%) 38 (14%) 7 (5%)
Vanderbilt University Medical Center 9 (8%) 23 (8%) 6 (5%)
Medical College of Wisconsin 5 (4%) 11 (4%) 6 (5%)
Washington University Medical Center 2 (2%) 1 (<1%) 1 (1%)
Mofﬁtt Cancer Center 4 (3%) 18 (6%) 10 (8%)
Memorial Sloan-Kettering Cancer Center 0 (0%) 5 (2%) 3 (2%)
Case type, n (%) Incident 69 (60%) 165 (59%) 76 (59%) P ¼ .99
Prevalent 46 (40%) 114 (41%) 52 (41%)
Age at cohort registration, median (min, max), yr 31 (19,40) 51 (41,59) 63 (60,79) NA
Gender, n (%) Female 59 (51%) 119 (43%) 47 (37%) P ¼ .07
Race, n (%) White 98 (85%) 256 (92%) 116 (91%) P ¼ .31
Asian 7 (6%) 8 (3%) 7 (5%)
African American 3 (3%) 7 (3%) 3 (2%)
Other 7 (6%) 8 (3%) 2 (2%)
Months from HCT to cGVHD onset, median
(min, max)
7.0 (2.2, 291) 7.7 (1.2, 57.6) 7.3 (2.5, 24.6) P ¼ .60
Months from cGVHD onset to enrollment, median
(min, max)
1.8 (0, 28.2) 1.8 (0, 32.5) 1.4 (0, 29.3) P ¼ .75
Diagnosis, n (%) AML 52 (45%) 77 (28%) 49 (38%) P < .001
ALL 19 (17%) 34 (12%) 3 (2%)
CML 7 (6%) 20 (7%) 1 (1%)
CLL 3 (3%) 18 (6%) 21 (16%)
MDS 6 (5%) 48 (17%) 27 (21%)
NHL 8 (7%) 51 (18%) 14 (11%)
HD 10 (9%) 3 (1%) 1 (1%)
MM 1 (1%) 23 (8%) 4 (3%)
AA 4 (3%) 0 (0%) 1 (1%)
Other 5 (4%) 5 (2%) 7 (5%)
Disease status, n (%) Early 38 (33%) 82 (29%) 45 (36%) P ¼ .65
Intermediate 45 (39%) 126 (45%) 50 (40%)
Advanced 32 (28%) 70 (25%) 31 (25%)
Transplant source, n (%) Bone marrow 22 (19%) 13 (5%) 3 (2%) P < .001
Cord blood 5 (4%) 10 (4%) 5 (4%)
Peripheral blood 88 (77%) 256 (92%) 120 (94%)
Transplantation type Myeloablative 85 (74%) 181 (65%) 38 (30%) P < .001
Nonmyeloablative/reduced-intensity 30 (26%) 96 (35%) 88 (70%)
Donor-patient CMV status Patient and donor both CMV negative 33 (30%) 106 (38%) 36 (28%) P ¼ .08
Patient or donor CMV positive 78 (70%) 171 (62%) 92 (72%)
Donor-patient gender Female into male 32 (29%) 70 (25%) 40 (32%) P ¼ .36
Donor match Match related 37 (32%) 128 (46%) 54 (42%) P ¼ .16
Match unrelated 56 (49%) 113 (41%) 52 (41%)
Mismatched 21 (18%) 38 (14%) 22 (17%)
Prior acute GVHD Yes 72 (63%) 191 (68%) 78 (61%) P ¼ .26
Karnofsky performance status 80 59 (51%) 141 (51%) 70 (55%) P ¼ .05
<80 28 (24%) 98 (35%) 42 (33%)
Missing 28 (24%) 40 (14%) 16 (13%)
Total serum bilirubin 2 mg/dL 105 (92%) 261 (95%) 123 (97%) P ¼ .27
>2 mg/dL 9 (8%) 15 (5%) 4 (3%)
Platelet count <100 K/uL 19 (17%) 46 (17%) 21 (17%) P ¼ .99
100 K/uL 95 (83%) 232 (83%) 106 (83%)
NIH 0-3 cGVHD global severity score Moderate 63 (55%) 165 (59%) 74 (58%) P ¼ .73
Severe 52 (45%) 114 (41%) 54 (42%)
Sorror comorbidity index, median (min, max) 2 (0, 10) 2 (0, 11) 3 (0, 12) P ¼ .001
AML indicates acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myelogenous leukemia; CLL, chronic lymphoblastic leukemia;
MDS, myelodysplastic syndrome; NHL, non-Hodgkin lymphoma; HD, Hodgkin disease; MM, multiple myeloma; AA, aplastic anemia; CMV, cytomegalovirus;
cGVHD, chronic graft-versus-host disease.
Data presented are n (%), unless otherwise indicated.
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history of acute GVHD, disease status at the time of trans-
plantation, and severity of chronic GVHD. Compared with
AYA and middle-aged patients, older patients were more
likely to have received reduced or nonmyeloablative condi-
tioning and a peripheral blood stem cell graft, and they had a
different spectrum of diagnoses leading to transplantation
and a higher comorbidity burden (Table 1).Chronic GVHD Manifestations and Symptom Burden
Table 2 depicts the physician-reported global and organ
severity score at enrollment, according to age groups. Global
and organ severity scores did not differ according to age
groups, except for genital involvement, which was more
prevalent and severe in AYA patients (P ¼ .003).
The burden of chronic GVHD symptoms, as measured by
the Lee Chronic GVHD Symptom Scale, was similar between
Table 2
Physician-Reported Global and Organ Severity Score at Enrollment According to Age Groups
Site Score n Age  40 (n ¼ 115) n Age 40-60 (n ¼ 279) n Age  60 (n ¼ 128) P Value
Physician reported global score Mild 115 47 (41%) 278 126 (45%) 128 50 (39%) P ¼ .77
Moderate 55 (48%) 122 (44%) 61 (48%)
Severe 13 (11%) 30 (11%) 17 (13%)
Skin None 115 39 (34%) 279 107 (38%) 128 38 (30%) P ¼ .62
Mild 26 (23%) 51 (18%) 26 (20%)
Moderate 29 (25%) 72 (26%) 34 (27%)
Severe 21 (18%) 49 (18%) 30 (23%)
Mouth None 115 47 (41%) 279 107 (38%) 128 44 (34%) P ¼ .68
Mild 51 (44%) 122 (44%) 63 (49%)
Moderate 14 (12%) 41 (15%) 20 (16%)
Severe 3 (3%) 9 (3%) 1 (1%)
GI tract None 115 83 (72%) 279 186 (67%) 128 78 (61%) P ¼ .36
Mild 27 (23%) 70 (25%) 38 (30%)
Moderate 4 (3%) 22 (8%) 12 (9%)
Severe 1 (1%) 1 (<1%) 0 (0%)
Eye None 115 63 (55%) 279 128 (46%) 128 54 (42%) P ¼ .58
Mild 32 (28%) 96 (34%) 50 (39%)
Moderate 17 (15%) 46 (16%) 20 (16%)
Severe 3 (3%) 9 (3%) 4 (3%)
Joint and fascia None 115 81 (70%) 279 183 (66%) 128 92 (72%) P ¼ .23
Mild 22 (19%) 56 (20%) 27 (21%)
Moderate 12 (10%) 34 (12%) 9 (7%)
Severe 0 (0%) 6 (2%) 0 (0%)
Genital tract None 104 84 (81%) 260 227 (87%) 122 117 (96%) P ¼ .003
Mild 9 (9%) 21 (8%) 2 (2%)
Moderate 10 (10%) 7 (3%) 2 (2%)
Severe 1 (1%) 5 (2%) 1 (1%)
Lung None 115 48 (42%) 279 132 (47%) 128 50 (39%) P ¼ .15
Mild 45 (39%) 115 (41%) 58 (45%)
Moderate 22 (19%) 28 (10%) 19 (15%)
Severe 0 (0%) 4 (1%) 1 (1%)
Liver None 115 52 (45%) 278 123 (44%) 127 68 (54%) P ¼ .04
Mild 24 (21%) 82 (30%) 39 (31%)
Moderate 24 (21%) 50 (18%) 13 (10%)
Severe 15 (13%) 23 (8%) 7 (6%)
GI indicates gastrointestinal.
A. El-Jawahri et al. / Biol Blood Marrow Transplant 20 (2014) 1341e13481344age groups in the unadjusted analyses. Interestingly, subscale
analysis showed that older patients had lower psychological
symptom burden (median score: older, 16.7; middle-aged,
25.0; AYA, 25.0; P ¼ .001) compared with AYA and middle-
aged patients (Figure 1). In the multivariable analyses, older
patients reported similar overall chronic GVHD symptom
burden to AYA and middle-aged patients (Table 3).
Age and Patients’ Functional Status and Physical Fitness
As depicted in Figure 1, older patients had a lower func-
tional status as measured by the 2-MWT, comparedwith AYA
and middle-aged patients (P ¼ .003). After adjusting for
clinical covariates (Table 3), the 2-MWT for older patientswas
estimated to be 53.8 feet lower than AYA patients (P < .001)
and 35.0 feet lower than middle-aged patients (P ¼ .001).
The maximal, adjusted, and modiﬁed HAP scores were
also signiﬁcantly lower for older patients in the unadjusted
analysis compared with AYA and middle-aged patients (P <
.001, Figure 1). In the multivariable analyses (Table 3), older
patients reportedmodiﬁed HAP scores that were comparable
to middle-aged patients (estimate -1.7, P¼ .22) but 8.9 points
lower than AYA patients (P < .001).
Age and Patient-reported QOL
Despite lower physical ﬁtness and functional status, older
patients reported preserved QOL compared with younger
patients. As depicted in Figure 1, FACT-BMT scores were
higher for older patients compared with middle-aged pa-
tients and similar to AYA patients (median scores: older, 109;
middle-aged, 102; AYA, 106; P ¼ .01). Similar trends wereseen with FACT-General (G) and FACT-BMT TOI scores (see
supplemental data online).
After adjusting for clinical covariates (Table 3), older and
AYA patients had comparable FACT-BMT scores, which were
approximately 5.7 points higher than middle-aged patients
scores (older versus middle-aged, P ¼ .004; AYA versus
middle-aged, P ¼ .007). Similarly, FACT-G and FACT-BMT TOI
scores were comparable between AYA and older patients and
signiﬁcantly higher than those of middle-aged patients
(Table 3).
In the univariate analysis, we did not detect any signiﬁ-
cant differences in physical component scores and mental
component scores of the SF-36 between age groups. How-
ever, older patients did report lower SF-36 physical func-
tioning scores compared with AYA and middle-aged patients
(median scores: older, 38.1; middle-aged, 42.3; AYA, 46.5;
P ¼ .003) but less bodily pain (P ¼ .007). After adjusting for
clinical covariates (Table 3), SF-36 physical component scores
and mental component scores were similar across all age
groups.
Age and Nonrelapse Mortality and Overall Survival
Figure 2 depicts overall survival curves and cumulative
incidence of nonrelapse mortality for all age groups since
study enrollment. Older age was not associated with higher
nonrelapse mortality or lower overall survival in the unad-
justed analyses. In multivariable analyses, older patients had
a similar hazard ratio (HR) of death compared with middle-
aged patients (HR, 1.001; 95% conﬁdence interval [CI], .63
to 1.57; P ¼ .99) and AYA patients (HR, 1.66; 95% CI, .91 to
Figure 1. QOL, psychological symptoms, physical ﬁtness, and functional status comparison between age groups at study enrollment. The bar height represents the
medians in each group. The P values reported reﬂect the overall comparison across all age groups.
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signiﬁcantly different between age groups (older versus
middle-aged: HR, .85; 95% CI, .46 to 1.50; P ¼ .59; younger
versus middle-aged: HR, .53; 95% CI, .26 to 1.00; P ¼ .06).
Similar results were obtained when examining nonrelapse
mortality and overall survival since chronic GVHD diagnosis
(data not shown).
Subgroup Analysis of the Older Patient Cohort
To examine the inﬂuence of age in the older cohort of
patients, we performed a subgroup analysis comparing
outcomes in the following patient subgroups: ages 60 to 64
(n ¼ 73), ages 65 to 69 (n ¼ 39), and ages  70 (n ¼ 16). We
did not detect differences in overall and organ-speciﬁc
chronic GVHD manifestations, QOL, physical and functional
status, or overall survival between these age groups, except
for more moderate-severe skin involvement in patients 65 to
69 years old (data not shown).
DISCUSSION
In this study, we examined the association of age and
clinical outcomes of HCT survivors with moderate to severe
chronic GVHD. Clinical manifestations and the symptom
burden of chronic GVHD were similar between patients in
different age groups. Despite having signiﬁcantly higher
physical limitations and more impaired functional abilities,
older patients with chronic GVHD reported relatively pre-
served QOL compared with younger patients. Furthermore,
nonrelapse mortality and overall survival were similar be-
tween older and younger patients with moderate to severe
chronic GVHD.
To the best of our knowledge, this study is the ﬁrst to
examine the relationship between age and the outcomes and
experience of patients with chronic GVHD. Our ﬁndingssuggest that age does not have an independent effect on QOL
or survival in patients with moderate or severe chronic
GVHD. These are important ﬁndings, as there has been an
increasing utilization of allogeneic HCT for older patients in
the recent years [31-34]. Our data suggest that older patients
with moderate or severe chronic GVHD cope well with their
physical limitations and have a reasonable QOL, supporting
the notion that age alone should not be a limiting factor for
consideration of allogeneic HCT.
Interestingly, we noted a U-shaped relationship be-
tween age and QOL, with middle-aged patients reporting a
signiﬁcantly lower QOL compared with both AYA and older
patients, which is also considered a clinically meaningful
difference in QOL scores [24]. Others have also reported
lower QOL in middle-aged compared with older patients
with advanced heart failure and other chronic illnesses
[35,36]. This has been attributed to the balance between
the degree of limitations and patients’ expectations
regarding what their QOL ought to be. In our study, AYA
patients appear to have the least physical limitations
compared with the older cohorts, which is likely respon-
sible for their reported better QOL. Despite similar
functional limitations and symptom burden between
middle-aged and older patients, QOL was signiﬁcantly
lower in the middle-aged cohort. Middle-aged patients
may have higher expectations and demands in terms of
their functional goals leading to more difﬁculty in coping
with the effects of their disease and a steeper decrement in
QOL [35,37]. Additionally, several of our measures sug-
gested that older patients had lower psychological symp-
tom burden and better emotional well-being, which can
also partly explain the preserved QOL seen in older pa-
tients. Thus, the middle-aged population appears to be the
most vulnerable to the burden of chronic GVHD and might
Table 3
Multivariable Comparison of QOL, Symptom Burden, and Physical and Functional Status, Adjusted for Clinical Covariates Using All Visits
Characteristics Median (min, max) n Group Estimate of Difference 95% CI P Value
Lee Symptom Score 1692 Overall P ¼ .44
Age  40 1.1 3.5-1.2 P ¼ .33
Age  60 1.1 3.3-1.1 P ¼ .32
Age (40-60) 0 (reference)
FACT-G score 1664 Overall P ¼ .003
Age  40 3.6 .5-6.8 P ¼ .02
Age  60 4.5 1.5-7.5 P ¼ .003
Age (40-60) 0 (reference)
FACT-BMT total score 1662 Overall P ¼ .001
Age  40 5.7 1.5-9.9 P ¼ .007
Age  60 5.7 1.8-9.6 P ¼ .004
Age (40-60) 0 (reference)
FACT-BMT TOI 1676 Overall P ¼ .002
Age  40 4.3 1.3-7.4 P ¼ .005
Age  60 3.9 1.1-6.8 P ¼ .007
Age (40-60) 0 (reference)
SF36 Physical Component Scale 1642 Overall P ¼ .23
Age  40 1.7 .3-3.7 P ¼ .09
Age  60 .3 1.5-2.2 P ¼ .72
Age (40-60) 0 (reference)
SF36 Mental Component Scale 1642 Overall P ¼ .10
Age  40 1.3 .8-3.4 P ¼ .22
Age  60 2.0 .02-4.0 P ¼ .05
Age (40-60) 0 (reference)
Two-minute walk test 1655 Overall P < .001
Age  40 18.8 2.5-40.2 P ¼ .08
Age  60 35.0 56.5-(13.5) P ¼ .001
Age (40-60) 0 (reference)
HAP maximal activity score 1696 Overall P < .001
Age  40 6.1 3.7-8.4 P < .001
Age  60 1.0 3.1-1.2 P ¼ .39
Age (40-60) 0 (reference)
HAP adjusted activity score 1696 Overall P < .001
Age  40 8.1 4.8-11.3 P < .001
Age  60 1.5 4.4-1.5 P ¼ .34
Age (40- 60) 0 (reference)
Modiﬁed HAP adjusted activity score 1696 Overall P < .001
Age  40 7.3 4.4-10.2 P < .001
Age  60 1.7 4.3-1.0 P ¼ .22
Age (40-60) 0 (reference)
Middle aged cohort (40 to 60) is the reference group. The estimate of difference is the estimated difference in scores compared with the reference group (middle-
aged cohort) based on the results of the multivariable linear mixed linear using all visit data and adjusting for study site, race, Hispanic ethnicity, patient gender,
month from hematopoietic cell transplantation (HCT) to cohort enrollment, disease diagnosis, conditioning regimen intensity, transplant source, National In-
stitutes of Health global chronic graft-versus-host disease (GVHD) severity, donor-patient gender match, donor match, Sorror comorbidity index, and overlap
versus classic chronic GVHD type. We repeated all analyses adjusting for prevalent versus incident cases instead of months from HCT to cohort enrollment and
obtained similar results (not shown).
A. El-Jawahri et al. / Biol Blood Marrow Transplant 20 (2014) 1341e13481346beneﬁt from targeted interventions designed to optimize
coping strategies and establishing realistic expectations in
dealing with their condition.Figure 2. (A) Overall survival and (B) cumulaAlthough our study is the ﬁrst to examine the association
of age on clinical outcomes in patients with moderate to
severe chronic GVHD, our ﬁndings are consistent withtive incidence of nonrelapse mortality.
A. El-Jawahri et al. / Biol Blood Marrow Transplant 20 (2014) 1341e1348 1347previous investigations examining QOL after allogeneic HCT
in older patients [5]. In 1 study of 160 older patients un-
dergoing allogeneic HCT, patients reported good-to-excellent
QOL despite signiﬁcant functional impairment and symptom
burden [5]. However, others have reported age as an
important predictor of lower QOL in patients undergoing
autologous and allogeneic HCT [1-4]. These discrepancies
could be due to the heterogeneity of the patient population
and the instruments used to measure QOL, the timing of QOL
measurement, and methodological limitations when con-
trolling for signiﬁcant confounders. The strength of our study
stems from the inclusion of a large cohort of patients from a
multicenter prospective observational study, utilizing well-
validated instruments to measure important clinical out-
comes with a modern classiﬁcation of moderate to severe
chronic GVHD.
Our study has several important limitations. First, our
population was primarily white and non-Hispanic, thereby
limiting the generalizability of our ﬁndings. Second, the
majority of our older patient cohort comprised patients be-
tween the ages of 60 to 64. Although, in a subgroup analysis,
we did not detect signiﬁcant differences in clinical outcomes
between patients in the 60 to 64 age group and those who
were older, it is possible that the small sample size of in-
dividuals above the age of 65 limited our ability to detect
clinically meaningful differences in QOL or survival. Third, it
is important to note that older patients in this cohort are a
select group carefully chosen to undergo HCT and who have
survived long enough to develop chronic GVHD. Therefore,
our data do not imply that all older individuals can undergo
transplantation with relatively preserved long-term out-
comes. Finally, it is hard to fully ascertain whether the
signiﬁcantly worse physical and functional limitations re-
ported by older patients in this study are due to their
advancing age, the burden of moderate to severe chronic
GVHD, the impact of therapies for chronic GVHD (including
systemic steroid use), or the combination of these factors.
In summary, older patients carefully selected for HCTwho
develop chronic GVHD have a relatively preserved QOL and
similar overall survival compared with younger patients,
despite a high degree of physical and functional limitations.
As the safety and efﬁcacy of allogeneic HCT is improving for
older patients, it is noteworthy that older survivors of allo-
geneic HCT with moderate to severe chronic GVHD have
encouraging long-term outcomes in terms of survival,
symptom burden, and QOL. Therefore, age itself should not
be considered a negative predictor of clinical outcomes in
patients with moderate to severe chronic GVHD, and fear of
the impact of chronic GVHD on the outcomes, symptom
burden, and QOL in older patients should not be used as a
contraindication for allogeneic HCT.ACKNOWLEDGMENTS
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